TORRENT PHARMACEUTICALS L vs WANBURY LIMITED

A side-by-side comparison of TORRENT PHARMACEUTICALS L (TORNTPHARM) and WANBURY LIMITED (WANBURY) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads TORNTPHARM vs WANBURY on 8 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability22
  • Growth10
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

77.50
P/E ratio
13.43
18.67
P/B ratio
6.17
0.76%
Dividend yield
0.00%
₹63.92
EPS
₹18.93

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

27.40%
Return on equity
45.52%
15.00%
Return on capital
31.00%
33.00%
EBITDA margin
15.86%
15.29%
Net margin
10.17%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

13.27%
Revenue CAGR (3Y)
9.15%
19.75%
Profit CAGR (3Y) even

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.68L Cr
Market cap
₹887 Cr
₹13,980 Cr
Revenue
₹650 Cr
₹2,138 Cr
Net profit
₹66 Cr
1.69
Debt / equity
1.55
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
WANBURY LIMITED
  • + ["Company has delivered good profit growth of 47.8% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 82.6%"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 10.6% over past five years.", "Tax rate seems low", "Promoters have pledged 62.2% of their holding."]
TORRENT PHARMACEUTICALS L full analysis WANBURY LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

TORNTPHARM vs WANBURY: Share Price, Valuation & Which to Buy | DocStoX